麦金
2021-03-18
该公司预计，这种名为aducanumab的药物将在6月7日之前获得批准，这是美国食品和药物管理局规定的日期。
UPDATE 1-Biogen full-year adjusted profit forecast assumes Alzheimer's drug approval
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":327850557,"tweetId":"327850557","gmtCreate":1616077537379,"gmtModify":1616077537379,"author":{"id":3508971616244503,"authorId":3508971616244503,"authorIdStr":"3508971616244503","name":"麦金","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>该公司预计，这种名为aducanumab的药物将在6月7日之前获得批准，这是美国食品和药物管理局规定的日期。</p></body></html>","htmlText":"<html><head></head><body><p>该公司预计，这种名为aducanumab的药物将在6月7日之前获得批准，这是美国食品和药物管理局规定的日期。</p></body></html>","text":"该公司预计，这种名为aducanumab的药物将在6月7日之前获得批准，这是美国食品和药物管理局规定的日期。","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/327850557","repostId":2108766986,"repostType":2,"repost":{"id":"2108766986","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1612355204,"share":"https://www.laohu8.com/m/news/2108766986?lang=&edition=full","pubTime":"2021-02-03 20:26","market":"us","language":"en","title":"UPDATE 1-Biogen full-year adjusted profit forecast assumes Alzheimer's drug approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2108766986","media":"Reuters","summary":"(Adds details on forecast, background) Feb 3 (Reuters) - Drugmaker Biogen Inc on Wednesday prov","content":"<html><body><p>(Adds details on forecast, background)</p><p> Feb 3 (Reuters) - Drugmaker Biogen Inc on Wednesday provided a full-year adjusted profit forecast that included sales from its Alzheimer's drug being reviewed by the U.S. drug agency. </p><p> The company expects the drug, aducanumab, will be approved by June 7, the date set by the U.S. Food and Drug Administration. </p><p> The road to getting a regulatory approval for the drug has been rocky, with Biogen and partner Eisai Co Ltd scrapping two studies in March 2019 and reversing that decision a few months later.</p><p> An expert panel to the FDA had voted \"no\" to three questions related to whether a single successful large trial of aducanumab was enough evidence of the drug's effectiveness given the clear failure of a second large study. </p><p> Biogen expects 2021 adjusted profit of $17 to $18.5 per share. </p><p> (Reporting by Dania Nadeem and Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)</p><p>((Dania.Nadeem@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UPDATE 1-Biogen full-year adjusted profit forecast assumes Alzheimer's drug approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUPDATE 1-Biogen full-year adjusted profit forecast assumes Alzheimer's drug approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-03 20:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>(Adds details on forecast, background)</p><p> Feb 3 (Reuters) - Drugmaker Biogen Inc on Wednesday provided a full-year adjusted profit forecast that included sales from its Alzheimer's drug being reviewed by the U.S. drug agency. </p><p> The company expects the drug, aducanumab, will be approved by June 7, the date set by the U.S. Food and Drug Administration. </p><p> The road to getting a regulatory approval for the drug has been rocky, with Biogen and partner Eisai Co Ltd scrapping two studies in March 2019 and reversing that decision a few months later.</p><p> An expert panel to the FDA had voted \"no\" to three questions related to whether a single successful large trial of aducanumab was enough evidence of the drug's effectiveness given the clear failure of a second large study. </p><p> Biogen expects 2021 adjusted profit of $17 to $18.5 per share. </p><p> (Reporting by Dania Nadeem and Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)</p><p>((Dania.Nadeem@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2108766986","content_text":"(Adds details on forecast, background) Feb 3 (Reuters) - Drugmaker Biogen Inc on Wednesday provided a full-year adjusted profit forecast that included sales from its Alzheimer's drug being reviewed by the U.S. drug agency. The company expects the drug, aducanumab, will be approved by June 7, the date set by the U.S. Food and Drug Administration. The road to getting a regulatory approval for the drug has been rocky, with Biogen and partner Eisai Co Ltd scrapping two studies in March 2019 and reversing that decision a few months later. An expert panel to the FDA had voted \"no\" to three questions related to whether a single successful large trial of aducanumab was enough evidence of the drug's effectiveness given the clear failure of a second large study. Biogen expects 2021 adjusted profit of $17 to $18.5 per share. (Reporting by Dania Nadeem and Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)((Dania.Nadeem@thomsonreuters.com;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":218,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":93,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/327850557"}
精彩评论